Nasdaq · Healthcare
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
As-reported financials and recent SEC filings for ARROWHEAD PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$829.4M
Net income
$-1.6M
Net margin
-0.2%
Diluted EPS
$-0.01
ROE
-0.3%
P/E (TTM)
—
Market cap
$11.11B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $98.3M | $-601.1M | $-205.0M | $-178.5M | $-149.0M |
| Net income | $-1.6M | $-599.5M | $-205.3M | $-176.1M | $-140.8M |
| Diluted EPS | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →32026-06-17
View on EDGAR →8-K2026-06-16
View on EDGAR →144/A2026-05-19
View on EDGAR →144/A2026-05-19
View on EDGAR →144/A2026-05-19
View on EDGAR →42026-05-14
View on EDGAR →1442026-05-12
View on EDGAR →Go deeper on ARWR
Search ARROWHEAD PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.